#002581

[partsfe005]

Keating 002581 Thermostat RX, 5/16 X 8, 30 | PartsFe

Order Keating 002581 Thermostat RX, 5/16 X 8, 30 today! Shop Restaurant Equipment Parts & Accessories at PartsFe with same-day shipping, available at the best prices.

[partsfeca]

Keating 002581 Thermostat RX, 5/16 X 8, 30 | PartsFe

Order Keating 002581 Thermostat RX, 5/16 X 8, 30 today! Shop Restaurant Equipment Parts & Accessories at PartsFe with same-day shipping, available at the best prices.

[color-palettes]

Stars were made for falling - Submitted by somepersonthatshere

#005911 #002581 #008153 #000681 #6D8100

[biomedres]

Public Awareness about Tetanus - BJSTR Journal

Public Awareness about Tetanus by  Tooba Komal* in  Biomedical Journal of Scientific & Technical Research

https://biomedres.us/fulltexts/BJSTR.MS.ID.002581.php

Objective of the present study was to estimate the awareness of public about Tetanus. A total of 100 subjects participated in this study. The subjects were the students of Bahauddin Zakariya University Multan, Pakistan. Tetanus is a bacterial infection which causes the tightness of the muscles by affecting the nervous system. It can also be called as lockjaw because the contractions usually occur in the jaw and neck. These infections can be fatal up to 10-20% approximately. Clostridium tetani is the bacteria which causes Tetanus. It was concluded form our questionnaire base study that Tetanus is a bacterial disease. It is not transmitted from parents to children, and there is no need for surgery, although medicines and vaccines can be given.  Tetanus is a bacterial infection which causes the tightness of the muscles by affecting the nervous system. It can also be called as lockjaw because the contractions usually occur in the jaw and neck. If not cured, this infection can be life threatening. These infections can be fatal up to 10-20% approximately. Clostridium tetani causes tetanus. Spores of this bacteria can be found in dust, soil or animal droppings. A deep wound or a cut can be the source of entrance of spores into the host which cause infection. Then these spores spread over the nervous system and produce tetanospasmin, a toxin. This poison blocks the nerve signals coming from spinal cord to the muscles causing stiffness in the neck, jaw, abdomen and chest muscles. It also leads to difficulty in swallowing and even cause sever muscle spasms. Its symptoms include increased rate of heart beat and blood pressure, fever, sweating. Antibiotics such as penicillin can be used for the treatment purposes to kill the bacteria. Vaccines against tetanus are also available. Muscle relaxers and toxin neutralizers can also be used to cure tetanus.

For more articles on Journal on Medical Science please click here

bjstr

Follow on Twitter : https://twitter.com/Biomedres01 Follow on Blogger : https://biomedres01.blogspot.com/ Like Our Pins On : https://www.pinterest.com/biomedres/

[takifuari]

7.00 TL Obje ve Boncuk Halka Küpe #ID2562 #KLS-002581 #KT612 #Küpe #ObjeveBoncukHalkaKüpe #TakıampAksesuar Daha fazlası için : www.takifuarietnik.com

[moneydjnews]

超級真菌致死率高 中國18例確診！陸製藥股飆數根漲停

抗藥性強、致死率高達6成的「超級真菌」耳念珠菌(Candida auris、見圖)席捲全球，中國最近幾年也淪陷、已有18個臨床感染案例確診。雖然目前無藥可解、但依舊有熱錢湧進中國製藥類股、股價紛紛大漲。

嘉實XQ全球贏家系統報價顯示，山東未名生物醫藥(002581.SZ)11日一度攻上漲停板(10%)，但盤中漲停打開；過去兩個交易日都以漲停板作收。江蘇聯環藥業(600513.SH)10日以漲停作收後，11日盤中也漲停鎖死。上海醫藥(2607.HK)開盤最高則一度跳漲逾5%。

財新傳媒、每日經濟新聞等陸媒10日報導，中國工程院院士廖萬清直指，中國已確認了18個耳念珠菌臨床感染病例。第一個已知感染病例是一名76歲腎臟有損傷的高血壓患者，此案已獲北京大學和中國科��院確認。

耳念珠菌會影響免疫系統較差的人，造成血液及傷口感染，對於一般的抗黴菌藥物具有頑強抗性，被美國疾病管制局(CDC)形容為「嚴…

[templatecatalog]

Premium Corporate Flyers Design 002581

Premium Corporate Flyers Design 002581

Premium Corporate Flyers Design 002581

This corporate flyer template was designed in Photoshop & Illustrator in PSD & EPS formats. The flyer template includes help file Illustrator EPS’s and Photoshop PSD’s. All PSD and EPS files are very well organized, proper name groups and layers. It’s very easy to edit and easy to insert images. Image placeholders are smart objects to make easy for you to…

[healthcarebiz]

Sinobioway Consortium Provides Update on Acquiring Sinovac Biotech (Nasdaq: SVA) at the Purchase Price of $8 Per Share

NEW YORK, Sep. 29, 2017 /PRNewswire/ -- Sinobioway Consortium has provided an update on its offer to acquire Sinovac Biotech (NASDAQ: SVA).

The Sinobioway Consortium has sent all the new documents required by the Special Committee in September 1st, though still no official response has been heard from the Special Committee or the Board of Sinovac so far, including the new offer up to $8 per share submitted months ago. To better accomplish the partitioning during this process, Sinobioway Consortium revised the fund arrangement to make sure their proposed transaction will be 100% funded by immediately available offshore US dollars which are not subject to any relevant governmental approval or foreign exchange supervision.

The Sinobioway Consortium is led by Dr. Pan, the Chairman of Shandong Sinobioway Biomedicine (SZE: 002581, a Chinese A-share listed company), and also the Co-founder of Sinovac and its principal operation subsidiary, Sinovac Beijing. As the Chairman of Sinovac Beijing, Dr. Pan owns veto power on matters such as expansion or amendment of creation of a mortgage or pledge upon the company's assets, a change in the organizational form of the company, and even the designation or removal of the general manager.

Moreover, the Consortium is also comprised of several reputable enterprises and private equity funds with offshore cash-rich funds, like CICC Qianhai Development (Shenzhen) Fund Management Co., Ltd., which currently manages several funds whose total value amounts to 1.7 billion CNY, and GoldStone Investment Co., Ltd., the wholly owned subsidiary of CITIC Securities Co., Ltd., which is the largest listed security company in China. Therefore, concerns on the transaction equity to acquire Sinovac should be unnecessary. 

On August 31st, Shandong Sinobioway Biomedicine has announced its semiannual financial report, which revealed that the revenue and net profit of Sinovac Beijing, the principal operation subsidiary of Sinovac, was 474.56 million CNY and 234.41 million CNY from January to June of 2017, respectively. Sinovac has realized its rapid growth of both revenue and net profit.

From the initial offer of $7 per share to the recent $8, Sinobioway Consortium has always bid higher than Mr. Yin's Consortium, and no matter what the cost will be, Sinobioway is capable of completing the Sinovac buyout and will never take giving up as its option.

View original content:http://ift.tt/2fCMjJh

Read this news on PR Newswire Asia website: Sinobioway Consortium Provides Update on Acquiring Sinovac Biotech (Nasdaq: SVA) at the Purchase Price of $8 Per Share

[takifuari]

7.00 TL Obje ve Boncuk Halka Küpe #ID2562 #KLS-002581 #KT612 #Küpe #ObjeveBoncukHalkaKüpe #TakıampAksesuar Daha fazlası için : www.takifuarietnik.com

[takifuari]

7.00 TL Obje ve Boncuk Halka Küpe #ID2562 #KLS-002581 #KT612 #Küpe #ObjeveBoncukHalkaKüpe #TakıampAksesuar Daha fazlası için : www.takifuarietnik.com

[takifuari]

7.00 TL Obje ve Boncuk Halka Küpe #ID2562 #KLS-002581 #KT612 #Küpe #ObjeveBoncukHalkaKüpe #TakıampAksesuar Daha fazlası için : www.takifuarietnik.com